Literature DB >> 10994001

Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease.

I Zerr1, M Pocchiari, S Collins, J P Brandel, J de Pedro Cuesta, R S Knight, H Bernheimer, F Cardone, N Delasnerie-Lauprêtre, N Cuadrado Corrales, A Ladogana, M Bodemer, A Fletcher, T Awan, A Ruiz Bremón, H Budka, J L Laplanche, R G Will, S Poser.   

Abstract

OBJECTIVE: To improve diagnostic criteria for sporadic Creutzfeldt-Jakob disease (CJD).
METHODS: Pooled data on initial and final diagnostic classification of suspected CJD patients were accumulated, including results of investigations derived from a coordinated multinational study of CJD. Prospective analysis for a comparison of clinical and neuropathologic diagnoses and evaluation of the sensitivity and specificity of EEG and 14-3-3 CSF immunoassay were conducted.
RESULTS: Data on 1,003 patients with suspected CJD were collected using a standard questionnaire. After follow-up was carried out, complete clinical data and neuropathologic diagnoses were available in 805 cases. In these patients, the sensitivity of the detection of periodic sharp wave complexes in the EEG was 66%, with a specificity of 74%. The detection of 14-3-3 proteins in the CSF correlated with the clinical diagnosis in 94% (sensitivity). The specificity (84%) was higher than that of EEG. A combination of both investigations further increased the sensitivity but decreased the specificity.
CONCLUSIONS: Incorporation of CSF 14-3-3 analysis in the diagnostic criteria for CJD significantly increases the sensitivity of case definition. Amended diagnostic criteria for CJD are proposed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10994001     DOI: 10.1212/wnl.55.6.811

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  92 in total

1.  14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis.

Authors:  Jérôme de Seze; Katel Peoc'h; Didier Ferriby; Tanya Stojkovic; Jean-Louis Laplanche; Patrick Vermersch
Journal:  J Neurol       Date:  2002-05       Impact factor: 4.849

2.  Progress in understanding Creutzfeldt-Jakob disease.

Authors:  Robin J Sellars; Donald A Collie; Robert J Will
Journal:  AJNR Am J Neuroradiol       Date:  2002-08       Impact factor: 3.825

3.  Comparative peptidome analyses of the profiles of the peptides ranging from 1-10 KD in CSF samples pooled from probable sporadic CJD and non-CJD patients.

Authors:  Cao Chen; Di Xiao; Wei Zhou; Yong-Chan Zhang; Qi Shi; Chan Tian; Jin Zhang; Chun-Xi Zhou; Jian-Zhong Zhang; Xiao-Ping Dong
Journal:  Prion       Date:  2012 Jan-Mar       Impact factor: 3.931

4.  14-3-3 proteins in neurological disorders.

Authors:  Molly Foote; Yi Zhou
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

Review 5.  Use of laboratory and imaging investigations in dementia.

Authors:  W M van der Flier; P Scheltens
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-12       Impact factor: 10.154

6.  Case 8: absentminded and "walking like a drunk".

Authors:  Matthew A Joenig; Justin McArthur
Journal:  MedGenMed       Date:  2005-02-03

7.  Multitracer PET imaging in Heidenhain variant of Creutzfeldt-Jakob disease.

Authors:  A Thomas; J C Klein; N Galldiks; R Hilker; M Grond; A H Jacobs
Journal:  J Neurol       Date:  2005-08-04       Impact factor: 4.849

8.  Re: Creutzfeldt-Jacob disease misdiagnosed as dementia with Lewy bodies.

Authors:  A J Larner
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

9.  Cerebrospinal Fluid Biomarkers in the Diagnosis of Creutzfeldt-Jakob Disease in Slovak Patients: over 10-Year Period Review.

Authors:  Silvia Koscova; Dana Zakova Slivarichova; Ivana Tomeckova; Katarina Melicherova; Martin Stelzer; Alzbeta Janakova; Dana Kosorinova; Girma Belay; Eva Mitrova
Journal:  Mol Neurobiol       Date:  2016-09-24       Impact factor: 5.590

Review 10.  Rapidly progressive dementia.

Authors:  Michael D Geschwind; Huidy Shu; Aissa Haman; James J Sejvar; Bruce L Miller
Journal:  Ann Neurol       Date:  2008-07       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.